医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
Konica Minolta, Inc. (“Konica Minolta”) (TOKYO: 4902) (ISIN: JP3300600008) and Innovation Network Corporation of Japan (“INCJ”) today announced the close of their joint acquisition of Ambry Genetics Corporation (“Ambry”) on October 19, 2017 (JST). Known as a pioneer and thought leader in genetic testing, Ambry is the first laboratory in the world to offer hereditary cancer panels and clinical exome sequencing.… 続きを読む
2017年10月20日 AM04:04
2017年10月20日
Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan
Regulatory News: Median Technologies (Paris:ALMDT), The Imaging Phenomics Company® today announces the appointment of Vivian Wang as General Manager, China and the appointment of Takashi Hayashi as Managing Director, Japan.… 続きを読む
2017年10月19日
Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that provide useful vision to blind patients, today announced the appointment of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific, where he will lead all commercial activities for the Company outside of North America.… 続きを読む
2017年10月18日
武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
武田薬品工業株式会社(TSE: 4502)は本日、クリゾチニブ投与中に進行した局所進行性/転移性未分化リンパ腫キナーゼ(ALK)陽性非小細胞肺がん(NSCLC)患者でALUNBRIGTM(ブリガチニブ)を評価するピボタル第2相ALTA(ALK in Lung Cancer Trial of AP26113/肺がんでALK阻害剤AP26113を検討する試験)臨床試験のデータが、日本標準時10月16日(月曜)午後4時30分~4時40分に、国際肺がん学会(IASLC)の第18回世界肺がん学会議(WCLC)のオーラルセッションで公表されると発表しました。口頭発表では本試験の2017年2月21日時点における安全性・有効性の最新データが発表されますが、それらは報告済みの臨床結果を引き続き支持するものです。… 続きを読む
2017年10月18日
Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
Shinkowa Pharmaceutical Co., Ltd. (Chuo-ward, Tokyo; CEO, Megumi Tanaka) sells the first ever original supplements and cosmetics containing β-nicotinamide mononucleotide (NMN) under the "MIRAILAB" supplement brand and the "MIRAIDA" cosmetic brand, respectively.The company has begun world-wide distribution of the special supplement products "NMN PURE 3000" and "NMN PURE 1500", which contain high doses of NMN.… 続きを読む